Citation Impact
Citing Papers
Prospective Study of Obstructive Sleep Apnea and Incident Coronary Heart Disease and Heart Failure
2010 Standout
Diet and Lifestyle Recommendations Revision 2006
2006 Standout
Direct transesterification of all classes of lipids in a one-step reaction.
1986 Standout
Effects of partially hydrogenated fish oil, partially hydrogenated soybean oil, and butter on serum lipoproteins and Lp[a] in men.
1995
Intake of trans fatty acids and risk of coronary heart disease among women
1993
Traffic Noise and Cardiovascular Risk: The Speedwell Study, First Phase. Outdoor Noise Levels and Risk Factors
1993
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Health effects of trans-fatty acids: experimental and observational evidence
2009
Aspirin for everyone older than 50?
2005
Primary Prevention of Coronary Heart Disease in Women through Diet and Lifestyle
2000 Standout
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018 Standout
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Perceived discrimination and health: A meta-analytic review.
2009 Standout
Albumin levels as a predictor of mortality in the healthy elderly
1992
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Pro-resolving lipid mediators are leads for resolution physiology
2014 StandoutNature
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
2014
Mammalian lipoxygenases and their biological relevance
2014
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
The changing landscape of atherosclerosis
2021 StandoutNature
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
2004 Standout
Trans Fatty Acids and Cardiovascular Disease
2006 Standout
Trans isomers of oleic and linoleic acids in adipose tissue and sudden cardiac death
1995
Acetylation by Histone Acetyltransferase CREB-binding Protein/p300 of STAT6 Is Required for Transcriptional Activation of the 15-Lipoxygenase-1 Gene
2001
Novel Docosatrienes and 17S-Resolvins Generated from Docosahexaenoic Acid in Murine Brain, Human Blood, and Glial Cells
2003 Standout
Adipose tissue isomeric trans fatty acids and risk of myocardial infarction in nine countries: the EURAMIC study
1995
The incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies II
2001
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
2007 StandoutNature
Helicobacter pylori Infection and the Development of Gastric Cancer
2001 Standout
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
2013
SGLT inhibitors in management of diabetes
2013
Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy
2014
Cardiovascular Effects of n-3 Fatty Acids
1988 Standout
Association of Fibrinogen, C-reactive Protein, Albumin, or Leukocyte Count With Coronary Heart Disease
1998 Standout
Abnormal membrane concentrations of 20 and 22-carbon essential fatty acids: A common link between risk factors and coronary and peripheral vascular disease?
1995
Effect of exposure to natural environment on health inequalities: an observational population study
2008 Standout
Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor
2015
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
2014
Non-alcoholic fatty liver disease
2021 Standout
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
2014
Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase
1999 Nature
Type 2 diabetes
2017 Standout
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
2014
The Composition of Bovine Milk Lipids: January 1995 to December 2000
2002 Standout
Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?
2016
12/15-Lipoxygenase Orchestrates the Clearance of Apoptotic Cells and Maintains Immunologic Tolerance
2012
Traffic Noise and Cardiovascular Risk. The Caerphilly Study, First Phase. Outdoor Noise Levels and Risk Factors
1988
Alternative Activation of Macrophages: Mechanism and Functions
2010 Standout
Helicobacter pyloriInfection
2002 Standout
Trans Fatty Acids and Coronary Heart Disease
1999
Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China
2004 Standout
Ferroptosis: mechanisms, biology and role in disease
2021 Standout
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
2014
Asymmetric Synthesis of 3‐Amino‐δ‐lactams and Benzo[a]quinolizidines by Catalytic Cyclization Reactions Involving Azlactones
2009
Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis
2000 Standout
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Alternative activation of macrophages
2003 Standout
A Prospective Study of Moderate Alcohol Consumption and the Risk of Coronary Disease and Stroke in Women
1988 Standout
STATs: transcriptional control and biological impact
2002 Standout
Sleep disturbance, stroke, and heart disease events: evidence from the Caerphilly cohort
2005
15-Lipoxygenase
2002
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
2015
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
2013
Cortisol, Testosterone, and Coronary Heart Disease
2005
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
2013
Chronic Kidney Disease Diagnosis and Management
2019 Standout
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Human inflammatory and resolving lipid mediator responses to resistance exercise and ibuprofen treatment
2013
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis
1987
IL-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats
2002
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
WHO Environmental Noise Guidelines for the European Region: A Systematic Review on Environmental Noise and Cardiovascular and Metabolic Effects: A Summary
2018 Standout
Dipeptidyl Peptidase IV and Its Inhibitors: Therapeutics for Type 2 Diabetes and What Else?
2013
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
1997 Standout
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity
2016 Standout
β-Selective C-Arylation of Silyl Protected 1,6-Anhydroglucose with Arylalanes: The Synthesis of SGLT2 Inhibitors
2015
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
2001 StandoutScience
LINOLEIC AND EICOSAPENTAENOIC ACIDS IN ADIPOSE TISSUE AND PLATELETS AND RISK OF CORONARY HEART DISEASE
1987
Dietary Carcinogens and Anticarcinogens
1983 StandoutScience
Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation.
1991
β-Selective C-Arylation of Diisobutylaluminum Hydride Modified 1,6-Anhydroglucose: Synthesis of Canagliflozin without Recourse to Conventional Protecting Groups
2015
Influence of Trans Unsaturated Fats on Experimental Atherosclerosis in Rabbits
1983
Monocyte 15-Lipoxygenase Expression Is Regulated by a Novel Cytosolic Signaling Complex with Protein Kinase C δ and Tyrosine-Phosphorylated Stat3
2006
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
2009 Standout
Trans‐18:1 acid content and profile in human milk lipids. Critical survey of data in connection with analytical methods
1998
Complete Field Guide to Asymmetric BINOL-Phosphate Derived Brønsted Acid and Metal Catalysis: History and Classification by Mode of Activation; Brønsted Acidity, Hydrogen Bonding, Ion Pairing, and Metal Phosphates
2014 Standout
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
2013
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
2015
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
2014
High 18:2 Trans-Fatty Acids in Adipose Tissue Are Associated with Increased Risk of Nonfatal Acute Myocardial Infarction in Costa Rican Adults
2003
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
2014
Contribution oftrans‐18∶1 acids from dairy fat to european diets
1994
Content and distribution oftrans‐18:1 acids in ruminant milk and meat fats. Their importance in european diets and their effect on human milk
1995
Dapagliflozin in Patients with Chronic Kidney Disease
2020 Standout
Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial
2013
12/15-Lipoxygenase, Oxidative Modification of LDL and Atherogenesis
2001
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
2013
Inverse regulation of lipid‐peroxidizing and hydroperoxyl lipid‐reducing enzymes by interleukins 4 and 13
1999
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study.
1994
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
2014
Works of Leo Thomas being referenced
Caerphilly and Speedwell collaborative heart disease studies. The Caerphilly and Speedwell Collaborative Group.
1984
Australian milkfat survey : fatty acid composition
1996
Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
2012
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
2011
Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
2011
Concentration of transunsaturated fatty acids in the adipose body tissue of decedents dying of ischaemic heart disease compared with controls.
1983
Interleukin-4 and -13 Induce Upregulation of the Murine Macrophage 12/15-Lipoxygenase Activity: Evidence for the Involvement of Transcription Factor STAT6
1998
Ischaemic heart disease and the proportions of hydrogenated fat and ruminant-animal fat in adipose tissue at post-mortem examination: a case-control study.
1981
Mortality from arteriosclerotic disease and consumption of hydrogenated oils and fats.
1975
Hydrogenated oils and fats: the presence of chemically-modified fatty acids in human adipose tissue
1981
Interleukin-4 and -13 Induce Upregulation of the Murine Macrophage 12/15-Lipoxygenase Activity: Evidence for the Involvement of Transcription Factor STAT6
1998
8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
2007
Concentration of 18:1 and 16:1 transunsaturated fatty acids in the adipose body tissue of decedents dying of ischaemic heart disease compared with controls: analysis by gas liquid chromatography.
1983
Ischaemic heart disease and consumption of hydrogenated marine oils in England and Wales.
1992